Jill A Parnell1, Teja Klancic2, Raylene A Reimer2,3. 1. Department of Health and Physical Education, Mount Royal University, Calgary, Alberta, Canada. 2. Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada. 3. Department of Biochemistry & Molecular Biology, Cumming School of Medicine, Calgary, Alberta, Canada.
Abstract
OBJECTIVE: To determine the effect of prebiotic supplementation on metabolic endotoxemia and systemic inflammation in adults with overweight and obesity. METHODS: Samples from a previously conducted randomized, double-blind, placebo-controlled trial were used for analysis. Participants were randomized to 21 g of oligofructose (n = 20; BMI 30.4 kg/m2 ) or a maltodextrin placebo (n = 17; BMI 29.5 kg/m2 ) for 12 weeks. A total of 37 participants had samples available for the current analysis. Resistin, adiponectin, plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and macrophage chemoattractant protein-1 (MCP-1) were quantified using MILLIPLEX® assays. Lipopolysaccharide (LPS) was measured using PyroGene™ Recombinant Factor C Assay. RESULTS:Plasma LPS concentrations were reduced by 40% in the oligofructose group over 12 weeks compared to a 48% increase in the placebo group (P = 0.04). PAI-1, a risk factor for thrombosis, was reduced to a greater extent in the oligofructose group (-17.3 ± 2.6 ng/ml) compared to the placebo group (-9.7 ± 1.8 ng/ml; P = 0.03). Oligofructose did not affect IL-6, TNF-α, MCP-1, adiponectin, or resistin. CONCLUSIONS:Oligofructose reduces metabolic endotoxemia and PAI-1. Incorporating prebiotics into the diet through supplements or functional foods may help mitigate some markers of obesity-associated inflammation.
RCT Entities:
OBJECTIVE: To determine the effect of prebiotic supplementation on metabolic endotoxemia and systemic inflammation in adults with overweight and obesity. METHODS: Samples from a previously conducted randomized, double-blind, placebo-controlled trial were used for analysis. Participants were randomized to 21 g of oligofructose (n = 20; BMI 30.4 kg/m2 ) or a maltodextrin placebo (n = 17; BMI 29.5 kg/m2 ) for 12 weeks. A total of 37 participants had samples available for the current analysis. Resistin, adiponectin, plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and macrophage chemoattractant protein-1 (MCP-1) were quantified using MILLIPLEX® assays. Lipopolysaccharide (LPS) was measured using PyroGene™ Recombinant Factor C Assay. RESULTS: Plasma LPS concentrations were reduced by 40% in the oligofructose group over 12 weeks compared to a 48% increase in the placebo group (P = 0.04). PAI-1, a risk factor for thrombosis, was reduced to a greater extent in the oligofructose group (-17.3 ± 2.6 ng/ml) compared to the placebo group (-9.7 ± 1.8 ng/ml; P = 0.03). Oligofructose did not affect IL-6, TNF-α, MCP-1, adiponectin, or resistin. CONCLUSIONS:Oligofructose reduces metabolic endotoxemia and PAI-1. Incorporating prebiotics into the diet through supplements or functional foods may help mitigate some markers of obesity-associated inflammation.
Authors: Valentina V Huwiler; Katja A Schönenberger; Alexander Segesser von Brunegg; Emilie Reber; Stefan Mühlebach; Zeno Stanga; Maria L Balmer Journal: Nutrients Date: 2022-06-24 Impact factor: 6.706
Authors: Kelsey H Collins; Walter Herzog; Graham Z MacDonald; Raylene A Reimer; Jaqueline L Rios; Ian C Smith; Ronald F Zernicke; David A Hart Journal: Front Physiol Date: 2018-02-23 Impact factor: 4.566
Authors: Jamie van Son; Laura L Koekkoek; Susanne E La Fleur; Mireille J Serlie; Max Nieuwdorp Journal: Int J Mol Sci Date: 2021-03-15 Impact factor: 5.923